GENETIC ANALYSIS NK -60 (8V8) - Total Liabilities
Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has total liabilities worth €25.37 Million EUR (≈ $29.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 8V8 operating cash flow to assess how effectively this company generates cash.
GENETIC ANALYSIS NK -60 - Total Liabilities Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's total liabilities have evolved over time, based on quarterly financial data. See GENETIC ANALYSIS NK -60 (8V8) shareholders funds for net asset value and shareholders' equity analysis.
GENETIC ANALYSIS NK -60 Competitors by Total Liabilities
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vivakor Inc
NASDAQ:VIVK
|
USA | $76.30 Million |
|
World Copper Ltd
V:WCU
|
Canada | CA$3.59 Million |
|
MW Trade S.A.
WAR:MWT
|
Poland | zł3.08 Million |
|
Atomic Minerals Corp
V:ATOM
|
Canada | CA$1.15 Million |
|
Maison Solutions Inc
NASDAQ:MSS
|
USA | $64.53 Million |
|
SKONEC Entertainment Co. Ltd.
KQ:276040
|
Korea | ₩6.33 Billion |
|
Diablo Resources Ltd
AU:DBO
|
Australia | AU$260.16K |
Liability Composition Analysis (2021–2025)
This chart breaks down GENETIC ANALYSIS NK -60's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GENETIC ANALYSIS NK -60 market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENETIC ANALYSIS NK -60's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual total liabilities of GENETIC ANALYSIS NK -60 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €25.37 Million ≈ $29.66 Million |
+27.57% |
| 2024-12-31 | €19.88 Million ≈ $23.25 Million |
-7.48% |
| 2023-12-31 | €21.49 Million ≈ $25.13 Million |
+5.95% |
| 2022-12-31 | €20.28 Million ≈ $23.71 Million |
+77.93% |
| 2021-12-31 | €11.40 Million ≈ $13.33 Million |
-- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more